• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Shenouda Maged

    5/29/24 9:24:53 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shenouda Maged

    (Last) (First) (Middle)
    C/O RELMADA THERAPEUTICS, INC.
    2222 PONCE DE LEON BLVD, 3RD FLOOR

    (Street)
    CORAL GABLES FL 33134

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RELMADA THERAPEUTICS, INC. [ RLMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/24/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $2.48 05/24/2024 A(1) 54,624 03/15/2024 12/15/2033 Common Stock 54,624 $0 136,714 D
    Stock Option (right to buy) $2.48 05/24/2024 J(2) 54,624 03/15/2024 12/15/2033 Common Stock 54,624 $0 82,090 D
    Explanation of Responses:
    1. On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares.
    2. On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer.
    /s/ Maged Shenouda 05/29/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RLMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    10/14/2022$81.00 → $8.00Buy → Neutral
    Goldman
    10/14/2022$90.00 → $10.00Buy → Hold
    Truist
    10/14/2022Buy → Neutral
    Guggenheim
    10/13/2022$64.00 → $7.00Outperform → Perform
    Oppenheimer
    12/20/2021$50.00 → $42.00Outperform
    SVB Leerink
    More analyst ratings

    $RLMD
    Financials

    Live finance-specific insights

    See more
    • Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the

      5/8/25 7:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial re

      3/27/25 4:05:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

      CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13751458Webcast Access: Click Here A replay of the webcast will be av

      3/26/25 9:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the

      5/8/25 7:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

      90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release "GEM/DOCE" formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point

      4/28/25 1:38:43 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

      CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. Abstract OverviewAbstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBCSession: Clinical Trials in Progress: Bladder CancerLocation: Hall C, The Square, Learning LabPresentation Date: April 28, 2025Presentation Time 10:04 AM PT to 10:12 AM PT    About NDV-01NDV-01 is an

      4/27/25 8:59:59 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      11/14/24 9:41:31 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      3/6/24 4:15:42 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      2/14/24 8:53:47 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    SEC Filings

    See more
    • SEC Form 424B5 filed by Relmada Therapeutics Inc.

      424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      4/28/25 1:46:21 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      4/28/25 1:18:07 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      3/27/25 4:42:38 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Traversa Sergio bought $395,115 worth of shares (140,000 units at $2.82), increasing direct ownership by 57% to 384,024 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      9/11/24 5:47:15 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Casamento Charles J bought $33,280 worth of shares (13,000 units at $2.56) (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      9/11/24 5:47:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Shenouda Maged bought $149,701 worth of shares (53,432 units at $2.80), increasing direct ownership by 153% to 88,335 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      9/11/24 5:46:42 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

      CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors. Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy

      1/12/23 8:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

      CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program.  Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise

      1/9/23 8:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

      Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla., July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. "My due diligence performed before joi

      7/21/22 8:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Relmada Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously

      12/5/24 8:17:30 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously

      9/17/24 7:49:37 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously

      6/5/24 7:16:28 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Casamento Charles J gifted 13,000 shares, closing all direct ownership in the company (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      10/23/24 4:27:07 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Traversa Sergio bought $395,115 worth of shares (140,000 units at $2.82), increasing direct ownership by 57% to 384,024 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      9/11/24 5:47:15 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Casamento Charles J bought $33,280 worth of shares (13,000 units at $2.56) (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      9/11/24 5:47:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care